Minor Cannabinoids: Current Evidence and Clinical Relevance in Patient Use

Minor cannabinoids, such as CBG, CBN, CBDV, THCA and CBDA, are gaining increased attention in both research and clinical settings. This presentation will provide a structured review of the current scientific understanding of minor cannabinoids, with an emphasis on pharmacology, receptor activity, metabolic pathways, and proposed mechanisms of action. The session will critically examine the existing preclinical and emerging human data, highlighting areas of promise as well as formulation considerations, bioavailability, and potential drug–drug interactions that are relevant to clinical decision-making. Real-world patient use will be explored through clinical experience and patient-reported outcomes, offering insight into how and why individuals are incorporating minor cannabinoids into their care. Common therapeutic indications, perceived benefits, safety concerns, and reasons for discontinuation will be reviewed. By integrating current evidence with real-world observations, this presentation aims to clarify where the science is well-supported, where significant gaps remain, and how minor cannabinoids are being used in therapeutic regimens today.
 

Learning Objectives:

1. Describe the pharmacology, receptor activity, metabolic pathways, and proposed mechanisms of action of key minor cannabinoids, including CBG, CBN, CBDV, THCA, and CBDA.

2. Evaluate the current preclinical and emerging human evidence for minor cannabinoids, including formulation considerations, bioavailability, and potential drug–drug interactions relevant to clinical practice.

3. Analyze real-world patient use of minor cannabinoids by identifying common therapeutic indications, perceived benefits, safety concerns, and reasons for discontinuation, while distinguishing areas of established evidence from ongoing knowledge gaps.